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GENERATING NOVEL EXPERIMENTAL TOOLS TO INTERROGATE 
HUMAN KIDNEY DEVELOPMENT 
ALLAN NIP 
ABSTRACT 
 
The kidneys are responsible for filtering out toxins, reabsorption of water, 
maintaining ion balance, as well as many other functions. Damage to the kidneys can be 
harmful to the body and even life threatening. Sudden damage to the kidney is 
categorized as acute kidney injury (AKI), while damage to the kidney over a long period 
of time, is known as chronic kidney disease (CKD). End-stage renal disease (ESRD) or 
kidney failure, is the last stage of CKD. At this stage, the kidneys are damaged to the 
point where they cannot function adequately for survival. Currently there is no cure for 
ESRD and kidneys at this stage require dialysis or a kidney transplant. Therefore, 
research on kidney diseases, development, and mechanisms will help reduce the number 
of patients with ESRD. 
Kidney development has been studied for decades but there are still many 
unanswered questions about nephrogenesis mechanisms, genetic factors, and biochemical 
pathways. Kidney organoids are a versatile tool used to study the functions of human 
kidneys. They originate from human pluripotent stem cells (hPSCs) which are derived 
from skin cells. After certain growth factors are added they function as miniature kidneys 
in a dish which acts as a platform for research in nephrogenesis, drug therapies, fibrosis, 
mutations and response to injury. Since these organoids are derived from hPSC, genome 
  vi 
editing techniques like CRISPR/Cas9 are able to introduce modifications and mutations 
to replicate certain diseases or specific differentiations. 
The aim of this project is to develop tools to better understand kidney 
development and ultimately improve kidney organoid models to make advances against 
kidney diseases, injuries, and complications. In this project we make genetic 
modifications to hPSCs using the iCRISPR platform to provide new experimental tools in 
kidney organoids. To create the iCas9 hPSC line we utilize a knockin strategy into the 
AAVS1 locus. We also worked on generating a Nephron Progenitor Cell (NPC) – 
specific fluorescent reporter hPSC line corresponding with CITED1. Our goal is to 
provide tools for potential use in CRISPR screening experiments, create the ability to 
have live imaging of NPC behavior, and provide easy identification and isolation of 
NPCs for downstream analysis.  
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INTRODUCTION 
 
Kidney Function 
 The physiological function of the kidney is the removal of metabolic waste from 
the body and the maintenance of fluid and ion balance. The kidney is able to filter blood 
with a structure called the nephron. The nephron is responsible for the absorption of 
water and electrolytes as well as the excretion of waste as urine1. Humans have 2 kidneys 
which both contain around 1 million nephrons each. If one kidney is damaged, the body 
is still able to survive with the one functioning kidney, although damage to both kidneys 
requires either dialysis or a kidney transplant. 
 
 
Kidney Development 
 In mammals, the kidney develops during embryogenesis and arises from the 
intermediate mesoderm germ layer. There are three stages of kidney development: the 
pronephros, the mesonephros, the metanephros. Each stage forms a kidney but the 
pronephros and the mesonephros are transient while the metanephros will ultimately form 
the adult kidney 2. The first two stages of kidney development are crucial for the 
formation of the final adult kidney. As the pronephros regresses, the caudal portion of the 
pronephric duct remains intact. This later becomes the Wolffian duct which is responsible 
for beginning the development of the next developmental stage, the mesonephros. During 
this stage the Wolffian duct connects with the urogenital sinus, which later differentiates 
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into the urinary bladder. In the mesonephros, mesonephric nephrons are formed but 
regress and are not present in the adult kidney. Reciprocal inductive signaling between 
the nephric duct and the metanephric mesenchyme (MM) cause budding of the posterior 
nephric duct forming the ureteric bud (UB) 3. During the regression of the mesonephros, 
the formation of the metanephric kidney begins by the UB branching out and coming into 
contact with the MM. The interaction between the UB and the MM induces branching 
and mesenchymal to epithelial differentiation leading to the formation of glomerular-
nephron-collecting duct systems. The ureteric bud outside of the MM elongates and 
differentiates to form the ureter 3. Repetitive branching of the UB will give rise to the 
renal collecting system and induce the formation of renal vesicles, the precursors of the 
nephron 8.  
 
 
Mesenchymal-to-Epithelial Transition 
 In humans the number of nephrons produced are dependent on a nephron-
restricted pool of mesenchymal progenitors 4. The number of nephrons produced is 
significant because an inadequate number of nephrons can increase the risk of kidney 
disease while aberrant progenitor differentiation can cause unregulated growth of 
nephroblast populations as seen in Wilms’ tumor patients 4. The ureteric bud and the 
metanephric mesenchyme contain a pool of progenitor cells which will become the 
majority of the cells found in the adult kidney 5. As stated previously, the interaction 
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between the UB and MM is important in the development of the adult kidney. Isolated 
MM will undergo apoptosis within 48 hours without the presence of the UB 7. There is a 
reciprocal inductive interaction between the two tissues. The UB produces signals that 
induce mesenchymal to epithelial transition (MET) in the MM while the MM produces 
signals promoting ureteric bud branching 6. The UB goes through branching 
morphogenesis within the MM. Mesenchymal cells that form the proximal nephron are 
known as nephron progenitor cells (NPCs) or cap mesenchyme. The NPCs undergo a 
mesenchymal to epithelial transition forming an epithelial tubule structure known as a 
renal vesicle. The renal vesicle eventually forms a mature nephron after differentiation 
and morphogenesis 5.  
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Figure 1: Ureteric Bud Development	-	Schematic representation of kidney development. 
The ureteric bud (gray) extends from the Wolffian duct, and, upon contact with the 
metanephric mesenchyme (red), reciprocal signaling induces both bud bifurcation and 
condensation of the mesenchyme to generate the cap mesenchyme. The blastemal 
mesenchyme then undergo a MET to generate the renal vesicle, which continues to form 
the comma-shaped and S-shaped body before the distal end fuses with the ureteric bud 
(which forms the collecting duct), and the proximal end joins to form the glomerulus, 
generating the mature nephron (dark orange) 24.		
 
 
The Cap Mesenchyme 
 The cap mesenchyme undergoes MET and will eventually form most of the 
epithelia of the nephron 12. Within the cap mesenchyme (CM), the genes SIX2 and 
CITED1 are expressed by NPCs and are responsible for generating all segments of the 
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nephron 13. The function of SIX2 is to suppress the ectopic formation of pre-tubular 
aggregates on the distal side of the uretic bud tip. Without the presence of SIX2, the CM 
will undergo premature MET to renal vesicles causing a premature end to nephrogenesis 
14. Along with SIX2, the Wnt pathway also regulates self-renewal and commitment of 
nephron progenitors 15. Another gene associated with the CM is Wt1. Expression of Wt1 
increases as the CM progenitors differentiate and the gene promotes differentiation 
towards the epithelial phenotype. The expression pattern of Wt1 indicates that it plays a 
main role in MET regulation as well as podocyte maturation 16. Wt1 regulates the 
expression of many genes involved with kidney development and has been referred to as 
a master control gene 17. Bmp7, a target gene of Wt1, is highly expressed during early 
kidney development in renal progenitor cells 18. Bmp7 null embryos exhibit a premature 
loss of progenitor population resulting in poorly developed kidneys 19. As the CM 
undergoes MET it will eventually form renal vesicles which will proliferate s-shaped 
bodies. Endothelial precursors infiltrate the s-shaped bodies to form the glomerular tuft, 
consisting of podocytes and the glomerular basement membrane 20. As the cap 
mesenchyme undergoes MET, SIX2 and CITED1 expression decrease 21.  
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SIX2 and CITED1 
 The two transcriptional regulators, SIX2 and CITED1, are linked with the self-
renewing population of nephron progenitor cells in the cap mesenchyme 22. Studies show 
that in SIX2 null mice metanephric hypoplasia developed, suggesting that SIX2 is 
required for nephron progenitor cell self-renewal 23. Loss of SIX2 leads to rapid decline of 
NPCs and ectopic epithelization 24. CITED1, (CBP/p300-interacting transactivators with 
glutamic acid [E]/aspartic acid [D]-rich C-terminal domain), acts a bifunctional 
transcriptional regulator, activating TGF-B and BMP signaling and repressing WNT-
dependent and B-catenin responses 25 26. The TGF-B signaling pathway is important in 
embryo development regulating cell growth, cell differentiation, and apoptosis. 
Therefore, CITED1 may be an important regulator of cellular responses during renal 
development. Overexpression of CITED1 inhibits UB branching and epithelial 
morphogenesis 26. On the other hand, a study showed that CITED1 null mice with normal 
nephrogenesis indicating that CITED1 expression is not completely subject to controlling 
maintenance of NPCs 27. Another study illustrated that decreased CITED1 expression 
induced progenitor cells to form pretubular aggregates with a burst of proliferation. This 
suggests that CITED1 can regulate cellular quiescence of the cap condensate as well as 
prevent premature nephronic differentiation 26.      
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 Wilms’ tumor, or nephroblastoma, is the most common renal malignancy of 
children. The cancer closely mirrors the triphasic histology of the embryonic kidney: 
blastema, epithelia, stroma. The blastemal compartment modeling the neoplastic 
analogue of the developing MM 27. Understanding the pathways of Wilms’ tumor may 
provide insight on how to treat the cancer as well as provide a model on developing MM. 
SIX2 and CITED1 expression decreases as the kidney develops but in Wilms’ tumor 
CITED1 remains active and labels the blastema. Overexpression of CITED1 in Wilms’ 
tumor enhances proliferation of NPCs while the deletion of the transcriptional regulator 
reduces Wilms’ tumorigenesis 27. The function of SIX2 in Wilms’ tumor is undefined 27.  
 
Kidney Organoids 
 New advances in research using human pluripotent stem cells (hPSCs), which 
includes both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), 
have opened up the opportunity to study mechanisms of human development and disease. 
hPSCs have the ability to self-renew indefinitely in culture while maintaining the ability 
to differentiate into any cell type in the human body. Research using hPSCs hope to give 
insight into unanswered questions about human embryonic development. There is still 
little knowledge on human embryonic development and a new model system is needed to 
make advances in the field. Studies on model organisms have provided the current 
knowledge of human development. Mouse models have been a great tool in researching 
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development but there are still limitations. There are around 1% of human genes with no 
identifiable mouse homologs leaving gaps of knowledge. Mouse models also do not fully 
replicate the features of human disease 30.  
Organoid models and research derived from iPSCs do not carry the ethical issues 
raised with the use of human blastocyst derived human embryonic stem cells 28. This 
allows greater flexibly for experimental models. iPSCs can also benefit research in other 
organ fields due to the nature of iPSCs. Recent protocols for creating 3D kidney 
organoids have provided a new way to investigate normal human kidney development. 
The organoids self-organize into structures containing glomeruli with cellular and spatial 
characteristics, tubules, interstitium, and vascular structures, paralleling human kidney 
infrastructure.  Kidney organoids have shown promise for many applications, including 
disease modeling, drug testing and screening, physiologic studies, and interrogation of 
developmental processes28. With all the potential benefits from kidney organoids, there 
are currently still significant limitations to them. A safety concern for the model is the 
possibly that human iPSCs can form tumors. Regenerative therapy using kidney 
organoids are not completely void of risk for tumor development because some 
populations of progenitor cells in the organoids may not be fully differentiated 29. Another 
limitation is the variability of iPSCs. Certain iPSCs have different optimal conditions and 
factors for kidney organoid growth. If organoids are generated from the same iPSC, 
heterogeneity must be taken into account. Measurement of functionality for the organoids 
is another current limitation. New technology is being researched and developed to better 
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quantify data and measurements. Absence of inflammatory cells in current kidney 
organoid protocols are another limitation on accuracy. Inflammatory cells in the human 
body play important roles and interactions in disease and disease repair. Organoid data 
and results must take into account the environment in which the organoids are cultured in 
28. Genome editing technology combined with kidney organoids have allowed 
development of powerful tools and models to study kidney development. Clustered 
regularly interspaced short palindromic repeats (CRISPR) - CRISPR-associated protein 9 
(Cas9) technology has allowed for specific genome editing and introducing genetic 
modifications to mimic human disease. CRISPR combined with kidney organoid models 
allow for insight into studying these human models 28.   
 
Overview of CRISPR-Cas9 
 The study of the CRISPR-Cas9 system began by accident in 1987. Short 
repetitive DNA sequences, 20-40 base pairs long, inter-spaced with nonrepetitive 
sequences were identified during research on a gene encoding alkaline phosphatase 
isozyme conversion enzyme (iap) in E. coli 31. Streptococcus pyogenes strains contain 
CRISPR-Cas loci that encode for the RNA-guided nuclease Cas9 32. This system allows 
for sequence-specific endo-nucleases to make precise editing of endogenous genomic 
loci. The Cas9 nuclease is guided by small RNAs via Watson and Crick base pairing with 
the target DNA sequence 33.  
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  Figure 2: Schematic of the RNA-guided Cas9 nuclease. The Cas9 nuclease 
from S. pyogenes (in yellow) is targeted to genomic DNA (shown for example is the 
human EMX1 locus) by an sgRNA consisting of a 20-nt guide sequence (blue) and a 
scaffold (red). The guide sequence pairs with the DNA target (blue bar on top strand), 
directly upstream of a requisite 5’-NGG adjacent motif (PAM:pink). Cas9 mediates a 
DSB ~3bp upstream of the PAM (red triangle) 33.   
 
Cas9 nuclease makes double strand breaks at the target genomic locus. Cleavage 
by Cas9 leads to two possible pathways for DNA damage repair: Non-homologous end 
joining (NHEJ) or Homology directed repair (HDR). NHEJ has no repair template and 
the double strand break created by Cas9 nuclease is re-ligated. This process is error prone 
and leaves the possibility of insertion/deletion (indel) mutations. This type of DNA repair 
is useful for gene knockouts because indels often lead to frameshift mutations and 
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premature stop codons 34. Compared to NHEJ, HDR occurs at a lower frequency and is 
more variable. Homology directed repair utilizes a repair template which gives HDR 
precise and defined modifications at desired target loci. The repair template can be 
comprised of double-stranded DNA constructs with homology arms flanking the insertion 
sequence or single-stranded DNA oligonucleotides (ssODNs) 35.  
 
Figure 3: DSB repair promotes gene editing. DSBs induced by Cas9 (yellow) can be 
repaired in one of two ways. In the error-prone NHEJ pathway, the ends of a DSB are 
processed by endogenous DNA repair machinery and rejoined, which can result in 
random indel mutations at the site of junction. Indel mutations occurring within the 
coding region of a gene can result in frameshifts and the creation of a premature stop 
codon, resulting in gene knockout. Alternatively, a repair template in the form of a 
plasmid or ssODN can be supplied to leverage the HDR pathway, which allows high 
fidelity and precise editing. Single-stranded nicks to the DNA can also induce HDR 33.  
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There are three types of CRISPR systems (I-III). Each system contains a cluster of 
Cas genes, noncoding RNAs and a distinct set of direct repeats. The direct repeats are 
interspaced by short variable sequences known as protospacers 36. These repeats and 
sequences form the CRISPR RNA (crRNA) array. Each protospacer is associated with a 
protospacer adjacent motif (PAM). The PAM is another aspect of the CRISPR system 
that allows for specificity because the nuclease can only cut if there is a PAM sequence 
downstream of the DNA sequence 37. The Type II CRISPR system utilizes the nuclease 
Cas9, the crRNA array, and an auxiliary trans-activating crRNA (tracrRNA) that help 
process the crRNA array in discrete units 33. The crRNA unit contains a 20-nucleotide 
guide RNA sequence and a partial direct repeat to direct the Cas9 nuclease to the DNA 
target of choice 33. The 20-nucloetide guide RNA can be modified to direct Cas9 to 
anywhere on the genome, creating a powerful tool for precise gene editing.   
 
Aims of Current Study 
 Given these recent advances in gene editing technologies and kidney organoid 
differentiation techniques, we reasoned that production of new genetic tools in hPSCs 
would allow for unprecedented studies of human kidney development. Thus, in this 
project, we aimed to use molecular cloning techniques to build foundational tools toward 
this end. First, we used CRISPR/Cas9-mediated homology-directed repair to generate an 
hPSC line capable of doxycycline-inducible expression of cas9 (iCas9 line). This line is 
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multifunctional, and it can be used to mediate further genetic modifications, for 
temporally inducible gene knockout, and lineage tracing strategies. Subsequently we used 
a similar strategy to produce a GFP knockin reporter allele into the human CITED1 
locus. This line will be used to fluorescently label the nephron progenitor cells during 
kidney organoid differentiation, as these cells are the critical regulators during renal 
development. 
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METHODS  
 
Inoculate Liquid Bacteria Culture 
 Grow up bacteria cultures from bacterial stab. Grow up plasmid in LB Broth. 20g 
of LB powder per 1L of H2O. 16 – 18 hour incubation at 37°C with shaking. 
 
Restriction Enzyme Digest 
 Restriction enzymes from New England Biolabs (NEB) and Thermo Fisher 
Scientific were used to prepare plasmid DNA for downstream experiments.  
 
Gel Electrophoresis  
 0.8% Agarose gel was used: 0.8g Agarose, 100ml of 1x TAE Buffer, 10µl of 
Ethidium Bromide. NEB Gel Loading Dye (6x) Purple was used to load DNA samples. 
1kb or 1000bp ladder was used. Gel were run at 130 V until dye has run ¾ length of the 
gel.  
 
 
QIAGEN Spin MiniPrep Kit 
 
 Purification of molecular biology grade plasmid DNA. Bacteria culture 
centrifuged down and pelleted. Bacterial pellet resuspended using Buffer P1. Buffer P2 
and Buffer N3 added respectively. Centrifuged for 10 mins at 17,900 x g in a table top 
microcentrifuge. 800µl of supernatant added to QIAprep 2.0 spin column. Centrifuge for 
30-60 seconds. Wash of QIAprep 2.0 spin column with Buffer PE and centrifuging. 
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Elution of DNA with Buffer EB and collection of DNA by centrifuging. Nucleic acid 
concentration (NAC) measure using Thermo Fisher Nanodrop 2000.  
 
QIAGEN Plasmid Plus Midi Kit 
 DNA purification of transfection-grade plasmid or cosmid DNA. Harvest 
bacterial culture by centrifuging at 6000 x g for 15 min at 4°C. Resuspend pellet with 
Buffer P1 and then add Buffer P2. Incubate at room temperature for 3 minutes. Add 
Buffer S3 and incubate at room temperature for 10 minutes. Extract lysate with QIAfilter 
Cartridge and add Buffer BB. Add lysate to QIAGEN Plasmid Plus spin column and 
apply vacuum to filter. Wash DNA with Buffer ETR and Buffer PE respectively. Remove 
residual wash buffer by centrifuge at 10,000 x g. Elute DNA from spin column with 
Buffer EB and centrifugation. Measure NAC using Thermo Fisher Nanodrop 2000.  
 
QIAquick Gel Extraction Kit 
 Extract and purify DNA from standard or low-melt agarose gels in TAE or TBE 
buffer. Excise digested DNA band on UV transilluminator. Add 3 volumes of Buffer QG 
to 1 volume of gel. Incubate gel at 50°C for 10 minutes until gel is completely dissolved. 
Add 1 gel volume of isopropanol to the sample and mix. To bind DNA add volume to 
QIAquick column and centrifuge at 10,000 x g for 1 minute. Wash with Buffer PE and 
discharge flow through. Elute DNA by adding 50ul of Buffer EB (10mM Tri-Cl, pH 8.5) 
to the QIAquick membrane. Collect DNA solution by centrifuging. Determine NAC with 
Thermo Fisher Nanodrop 2000.  
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Phosphorylation and Annealing of oligos pairs 
 1 reaction consist of 1µl of oligo 1 (Fwd) (100uM), 1ul of oligo 2 (Rev) (100uM), 
1µl of 10X T4 Ligation Buffer (NEB), 6.5µl ddH2O, 0.5µl T4 Polynucleotide Kinase 
(NEB). Total reaction volume 10µl. Anneal in thermocycler with the following program: 
37°C for 30 minutes, 95°C for 5 minutes and then ramp down to 25°C at 5°C/min.  
 
Ligation 
 Each ligation reaction contains: 50ng of digested plasmid. 1µl of phosphorylated 
and annealed oligo duplex, 1:200 dilution. 5µl 2X Quickligation Buffer (NEB). Xµl 
ddH2O. Subtotal 10µl. 1ul Quick Ligase (NEB) Total reaction volume 11µl. Incubate 
reaction at room temperature for 10 minutes.  
 
Transformation 
 Invitrogen Subcloning Efficiency DH5a Competent Cells used for 
transformations. 1µl (1-10 ng) of DNA added to 20µl of DH5a and mixed gently without 
pipetting. Incubated on ice for 30 minutes. Heat shock cells for 30 seconds in 42°C water 
bath without shaking. Incubate back on ice for 2 minutes. 80µl of S.O.C medium added 
to each tube. Incubate at 37°C for 1 hour with shaking. 50µl of transformation spread on 
to a LB plate containing antibiotic of choice. Incubate plates overnight at 37°C.   
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iProof High-Fidelity PCR Kit 
 20µl reactions: 4µl of 5X iProof HF/GC Buffer. 0.4µl (200 uM) dNTP mix. 
Primer 1 (0.5uM). Primer 2 (0.5uM). DNA Template (50-500ng depending on 
complexity of DNA). Xul H2O. 0.2µl iProof DNA Polymerase.  
Thermal Cycler Protocol: Initial Denaturation 98°C for 30s. Denaturation 98°C 5-10s. 
Annealing 45-72°C for 10-30s, 25-35 cycles. Extension at 72°C for 15-30 s / kb. Final 
extension 72°C 10 minutes.  
 
QIAquick PCR Purification Kit 
 Purification of PCR products. Add 5 volumes of Buffer PB to 1 volume of PCR 
sample. Bind DNA by applying sample to QIAquick column, centrifuge and discard flow 
through. Wash with Buffer PE. Centrifuge the column for an additional 1 minute to 
remove any residual ethanol from Buffer PE. Elute DNA by adding Buffer EB to the 
QIAquick membrane and extract by centrifugation.  
 
CRISPR/Cas9 mediated gene-editing in hESC/iPSCs: protocol for generation of 
cells with large knock-ins using targeting plasmids containing antibiotic selection 
marker 
Step 1: Reverse transfection of human iPSCs 
 Day 0: Prepare 4ug plasmid DNA to be used for transfection of 2 x 106 cells in 1 
well of a 12-well plate. Prepare a Matrigel-coated 12-well plate. Aspirate Matrigel and 
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add mTeSR1 + ROCK Inhibitor Y-27632. Place plate in incubator. Prepare transfection 
mix in 15ml Falcon tubes. OptiMEM-I, Plasmid DNA: Cas9 AAVS1 gRNA1, AAVS1-
Cas9, AAVS1-rtTA. Incubate at room temperature for 15-20 minutes. Begin iPSC 
harvest by adding 1 ml Accutase to each well and incubate for 5-10 minutes at 37°C. Add 
mTeSR1 + 10uM Y-27632 per well once majority of cells have rounded up. Centrifuge 
single cell suspension at 300 x g for 3 minutes. Add transfection reactions from 15ml 
Falcon tubes to 12-well plate. After centrifugation, aspirate supernatant and resuspend the 
cell pellet in 2ml mTeSR1 + 10 uM Y-27632 (2 x 106 cells per ml). Transfers 1ml of cells 
(2 x 106 cells per well) to each well. Transfer plate to the incubator and gently shake side 
to side and back and forth a few times to evenly distribute the cells across the well. 
Incubate at 4h at 37°C, 5% CO2. After 4 hours, gently add MEF-CM + 10uM Y-27632. 
Incubate overnight at 37°C, 5% CO2.  
Day 1: Media Replacement: Aspirate media from wells and replace with fresh 
MEF-CM. 
Day 2: Media Replacement: Aspirate media from wells and replace with fresh 
MEF-CM. 
 
Step 2a: Hygromycin selection 
 Day 3: Plating cells for hygromycin selection: Prepare a Matrigel-coated 12 well 
dish. Aspirate media and add Accutase to the transfected and untransfected wells. 
Incubate for 5-10 minutes at 37°C. Once the majority of cells have detached add mTeSR1 
+ 10uM Y-27632 per well. Pipette gently with p1000 micro pipettor to break up 
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remaining cell clumps to single cells. Transfer each single cell suspension to a 15ml 
conical tube. Determine cell number in each tube. Centrifuge tubes at 300 x g for 3 
minutes. Aspirate the supernatant and resuspend cell pellet in mTeSR1 + 10uM Y-27632 
at 1 x 105 cells/ml. Plate 1 well of untransfected cells plated at 2 x 105 cells/well. Return 
plate to incubator at 37°C, shake plate to evenly distribute cells.  
Day 4: Prepare mTeSR1 containing 50ng/ml hygromycin: Aspirate spent media 
from each well and replace with mTeSR1 + hygromycin. Return to plate incubator.  
 Day 5 – 10: continue hygromycin selection: Aspirate spent media and replace 
daily with mTeSR1 + 50ng/ml hygromycin: Return to plate incubator.  
 Day 11: Assess cell survival: If all untransfected cells are dead, stop selection. 
Several small cell clusters should be visible in wells plated with transfected cells. 
Aspirate spent media and feed wells (including untransfected well) with mTeSR1 (no 
antibiotic) to begin recovery. Return plate to incubator.  
 Day 12 ~ 20: Expansion of hygromycin-resistant cells: Continue feeding daily 
with mTeSR1 with no antibiotic. Ensure no cells recover in the untransfected well. Cells 
passaged when discrete colonies become large and when areas of the plate contained 
multiple smaller colonies became crowded.  
 
Step 2b: G418/neomycin selection: 
 Day 3: Plating cells for G418 selection: Prepare a Matrigel-coated 6-well dish. 
Aspirate media and add Accutase to the transfected and untransfected wells. Incubate for 
5-10 minutes at 37°C. Once the majority of cells have detached add mTeSR1 + 10uM Y-
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27632 per well. Pipette gently with a p1000 micropipettor to break up remaining cell 
clumps to single cells. Transfer each single cell suspension to a labelled 15ml conical 
tube. Determine cell number in each tube. Centrifuge tubes at 300 x g for 3 minutes. 
Aspirate the supernatant and resuspend cell pellet in mTeSR1 + 10uM Y-27632 at 5 x 104 
cells/ml. Aspirate Matrigel from plate and plate transfected cell suspension at 2ml/well (1 
x 105 cells/well). Plate 1 well of untransfected cells plated at 1 x 105 cells/well. Incubate 
at 37°C and shake plate gently to evenly distribute cells.  
 Day 4: Begin G418 selection: Prepare mTeSR1 containing 25ng/ml G418. 
Aspirate spent media from each well and replace with mTeSR1 + G418. Return to 
incubator.  
 Day 5-10: Continue G418 selection: Aspirate spent media and replace daily with 
mTeSR1 + 25ng/ml G418.  
 Day 11: Assess cell survival: If all untransfected cells are dead, stop selection. 
Several small cell clusters should be visible in wells plated with transfected cells. 
Aspirate spent media and feed wells (including untransfected well) with mTeSR1 with no 
antibiotic to begin recovery. Return to incubator.  
 Day 7 ~ 14: Expansion of G418 resistant cells: Continue feeding daily to mTeSR1 
with no antibiotic. No cells should recover in the untransfected well.  
 
Step 3: Cloning antibiotic resistant cells: 
Plating drug-resistant cells at cloning density 
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 Day 0: Prepare a Matrigel-coated plate. Prepare room temperature mTeSR1 
containing 1X CloneR. Add Accutase to each well of antibiotic-resistant cells and 
incubate for 5-10 minutes at 37°C. Once the majority of cells have detached add mTeSR1 
to each well. Pipette gently with p1000 micro pipettor to break up remaining cell clumps 
to single cells. Combine all antibiotic resistant cells into a single sterile 15ml conical 
tube. Determine cell number and transfer 500,000 cells to a new conical tube. This 
portion of cells will be frozen for storage. Centrifuge the rest of the cells at 300 x g for 3 
minutes. From Matrigel coated plate, aspirate off Matrigel and add mTeSR1 + CloneR to 
each well. Aspirate the supernatant from the centrifuged cells and resuspend in 1ml 
mTeSR + CloneR. Plate drug-resistant cells at cloning density: Plate 2x wells at 100 
cells/well by adding 2µl of the cell suspension/well.  
 Day 1 – 3: continue feeding with mTeSR1 + CloneR. Day 1: no media change. 
Day 2: aspirate media and add 2ml mTeSR1 + CloneR. Day 3: add 0.5ml mTeSR1 + 
CloneR (do not aspirate any media) 
 Days 4 – 9: feed daily with antibiotic containing media. Daily aspirate spent 
media and replace with fresh mTeSR1 containing hygro/G418. Check clone growth each 
day and compare growth rate to clones with no antibiotic condition.  
 
 Prepare a Matrigel-coated well TC dish. Aspirate Matrigel from dish and add 
mTeSR1 to each well. Place dish in incubator to prewarm. Aspirate spent media from one 
well of the plate containing clones and add Gentle Cell Dissociation Reagent (GCDR). 
Incubate at room temperature for 3 minutes. Aspirate GCDR and add mTeSR1.  
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Picking clones: Identify the clone you wish to excise. Colony should be clearly 
separate from all other colonies. Use p200 micropipette, gently scrape the colony while 
pulling media into the pipette tip. Add the aspirated colony clumps into single well of 
plate. Gently triturate the clumps to break them into uniform pieces. Repeat depending on 
the number of clones desired. Once all the clones are picked, return to incubator and 
shake to distribute material evenly.  
Initial expanding of the clones: Monitor clones daily to ensure normal growth and 
the absence of overt differentiation. Approximately 6 days after picking the clones should 
be ready of expansion. Prepare Matrigel-coated 24 well dishes and 1.5ml Eppendorf 
tubes. Aspirate media from wells containing clones and add GCDR and incubate for 3 
mins at room temperature. Aspirate the GCDR and add mTeSR1. Scrape each well with a 
cell scraper to break up contents. Transfer to each single well of the 24 well dish and 
transfer remaining material to Eppendorf tubes for genotyping. 24 well dish should be 
frozen down at -80°C.  
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RESULTS 
 
Generation of iCas9 hPSC line via knockin into AAVS1 Locus 
 
Two plasmids were obtained from Addgene: AAVS1-Neo-M2rtTA and Hygro-
Cas9 Donor. AAVS1-Neo-M2rtTA is a targeting vector used to introduce the tetracycline 
transactivator gene (rtTA) into one allele at the human AAVS1 locus, and it contains a 
Neomycin resistance gene. The Hygro-Cas9 Donor is a donor vector used to generate a 
Tetracycline-inducible Cas9 cassette at the other human AAVS1 locus allele, and it 
contains hygromycin selection. The AAVS1 locus is within the PPP1R12C gene on 
human chromosome 19. The PPP1R12C gene permits expression of CAG promoter-
driven transgenes 38.  
Validation of AAVS1-Neo-M2-rtTA Plasmid 
A bacterial culture was grown from an AAVS1-Neo-M2rtTA bacteria agar stab 
from Addgene. To ensure that the bacteria grown is correct, a number of quality tests 
were run. A restriction digest of the plasmid DNA was performed to verify that it was the 
correct donor vector. The size of the plasmid provided by Addgene is 10,080bp. Four 
restriction enzymes were used to verify. SpeI cuts once at cut site 2327bp. MluI cuts once 
at cut site 955bp. NotI cuts twice at cut sites 2314bp and 6166bp. HindIII cuts twice at 
cut sites 837bp and 5303bp.  
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Figure 4: Gel Image of AAVS1-Neo-M2-rtTA: 1kb Ladder: Lane 1: Undigested 
AAVS1 Plasmid. Lane 2: SpeI. Lane 3: MluI digest. Lane 4: NotI digest. Lane 5: HindIII 
digest 
 
 
The gel confirms that the plasmid DNA has all the cut sites tested and we can confidently 
assume that the plasmid DNA extracted from the bacterial culture is correct.  
 Next, we started working on our CRISPR/Cas9 system. The CRISPR Target 
Sequence Cloning Protocol from the Zhang Lab at MIT was followed. The CRISPR/Cas 
system can be used in mammalian cells by co-expressing S. pyogenes Cas9 (SpCas9) 
nuclease with a guide RNA. A SpCas9 expressing plasmid was obtained from Addgene. 
The plasmid, pSpCas9(BB)-2A-GFP, contained Cas9 from S. pyogenes with 2A-GFP as 
well as a cloning backbone for the sgRNA. The plasmid DNAs extracted from the 
bacteria were verified with restriction digests.  
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Figure 5: pSpCas9(BB)-2A-GFP NotI Digest: 1kb Ladder: Lane 3: Undigested Hygro-
Cas9. Lane 4: KpnI Digested Hygro-Cas9. Lane 7: Undigested pSpCas9(BB)-2A-GFP. 
Lane 8: NotI Digest pSpCas9(BB)-2A-GFP.  
 
 
 
Restriction enzyme NotI cuts pSpCas9(BB)-2A-GFP once at cut site 6544bp. The 
restriction enzyme should linearize the plasmid and express the size of pSpCas9(BB)-2A-
GFP which is 9288bp. With the band near the 9-10kb region, we are confident that the 
plasmid DNA is correct. Restriction enzyme KpnI cuts Hygro-Cas9 donor once at cut site 
10243bp. The digest should also linearize the plasmid and express the size of Hygro-Cas9 
donor, 10,896bp. The band in Lane 4 of the gel is above the 10kb band which suggest 
that the plasmid is correct. Gel purification was used to extract the digested plasmid. The 
QIAquick Gel Extraction Kit was used.   
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Oligo annealing and cloning into backbone vectors 
 The next step is to digest pSpCas9(BB)-2A-GFP with BbsI to open up to plasmid 
and prep it for insertion of the gRNA. BbsI cuts the plasmid twice at cut sites 245bp and 
267bp, which leaves non-compatible sticky end overhangs used to ligate gRNA oligo 
sequences. 6 pairs of gRNAs targeting the hAAVS1 locus were designed to cut at the 
human AAVS1 locus. 
 
Primer ID Name Sequence (5’-3’) 
001 hAAVS1 gRNA 1 Fwd CACCGctgtcccctccaccccacag 
002 hAAVS1 gRNA 1 Rev aaacctgtggggtggaggggacagC 
003 hAAVS1 gRNA 2 Fwd CACCgtcaccaatcctgtccctag 
004 hAAVS1 gRNA 2 Rev aaacctagggacaggattggtgac 
005 hAAVS1 gRNA 3 Fwd CACCgtcccctccaccccacagtg 
006 hAAVS1 gRNA 3 Rev aaaccactgtggggtggaggggac 
007 hAAVS1 gRNA 4 Fwd CACCGtccctagtggccccactgtg 
008 hAAVS1 gRNA 4 Rev aaaccacagtggggccactagggaC 
009 hAAVS1 gRNA 5 Fwd CACCGtgtccctagtggccccactg 
010 hAAVS1 gRNA 5 Rev aaaccagtggggccactagggacaC 
011 hAAVS1 gRNA 6 Fwd CACCggggccactagggacaggat 
012 hAAVS1 gRNA 6 Rev aaacatcctgtccctagtggcccc 
 
Table 1: hAAVS1 gRNAs: Targeting hAAVS1 Locus 
 
 
 
Each oligo contains a Fwd gRNA and a Rev gRNA.  Using the protocol from the Zhang 
Lab, each oligos pair was phosphorylated and annealed creating 6 total pairs. Next a 
ligation reaction was set up between the oligo pairs and the BbsI digested pSpCas9(BB)-
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2A-GFP. After the ligation reaction, the designed gRNAs are cloned into the SpCas9 
nuclease. Each gRNA ligation was transformed into DH5a competent cells and grown on 
LB Ampicillin plates overnight at 37°C. 5 out of the 6 transformation reaction plates 
produced colonies. gRNA 4 on plate 4 did not produce colonies. 2 colonies from each 
plate were picked to be grown up for a DNA MiniPrep extraction. 8 Total clones were 
collected. Cas9-GFP with hAAVS1 gRNAs: Clones 1, 2.1, 2.2, 3.1, 3.2, 5, 6.1, 6.2. 
Sanger sequencing was used to confirm ligation of the correct sgRNA sequences into the 
plasmid. These clones were stored at -20°C for downstream use.  
The three plasmids prepared, pSpCas9(BB)-2A-GFP with gRNA 1, Hygro-Cas9, 
AAVS1-Neo-M2rtTA, were used in the CRISPR/Cas9 mediated gene-editing in hESCs 
transfection protocol. To begin creating the iCas9 hPSCs we used CRISPR/Cas9 to 
mediate biallelic knockin of iCRISPR components into the AAVS1 locus of H9 human 
embryonic stem cells (hESCs). As shown in Figure 6, tetracycline transactivator (rtTA3) 
is knocked into one allele. A cassette for tet-responsive Cas9 expression is knocked into 
the other allele. The H9 cells were transfected with the three plasmids and simultaneously 
exposed to dual antibiotic selection with hygromycin and G418. Only cells that were 
successfully transfected with the plasmids would survive the antibiotic selections. 
Resistant H9 cells were sub-cloned and genotyped using allele-specific PCR reactions.  
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Figure 6: AAVS1 - iCas9 Knock-in Strategy:  
 
In the Wild Type (WT) AAVS1 locus, a PCR with Primers 52 and 54 will 
produce a 2323bp band. Cells successfully targeted will contain rtTA3 and Cas9 
constructs. Primers 45 and 54 produce a 1425bp band indicating the presence of rtTA. 
Primers 42 and 54 produce a 2172 bp band and indicate the presence of Cas9. 
Successfully transfected cells will not express a WT band after PCR with Primers 52 and 
54 due to the increased size with the rtTA3 and Cas9 inserts. The size of the band would 
be around 10kb which would not amplify during the PCR due to extension time and large 
inserts are difficult to amplify in PCR. As shown in the PCR gel in Figure 7, of the 
twelve genotyped subclones, 11 were correctly targeted with both the rtTA and Cas9 
constructs. Clone #5 contained three bands, suggesting it was a mixed population of cells.  
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Primer Name Sequence (5’-3’) 
042 hPPP1R12C-Cas9 screen INT Fwd 1 GTGGTAGATGGTGGGGTACT 
045 hPPP1R12C-rtTA screen INT Fwd 1 cacgctatctgtgcaaggtc 
052 hPPP1R12C screening EXT Fwd 2 cttcccctcttccgatgttg 
054 hPPP1R12C screening EXT Rev 3 accaaccatccctgttttcc 
 
Table 2: Designed Primers for iCas9 Knockin Strategy: 
Twelve sub-clones were selected from the transfection. Figure 7 shows genotyping of the 
twelve clones with allele-specific PCR reactions.  
  
 
 
Figure 7: Genotyping of twelve sub-clones using allele-specific PCR: The desired 
genotype are clones expressing a Cas9 and rtTA band with no WT. Eleven out of twelve 
clones express the correct genotype.  
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Table 3: List of H9-iCas9 Clones 
 
 To test the functionality of the inducibility of the cells, sub-clone 4 was exposed 
to doxycycline (1µg/ml) for 48 hours. The Hygro-Cas9 donor transfected into the cells 
contained a Tet Response Element (TRE). Refer back to Figure 6. TRE is 7 repeats of a 
nucleotide tetracycline operator (tetO) sequence, which is recognized by the tetracycline 
transactivator (tetTA). In the presence of doxycycline, an analog of tetracycline, tetTA 
will bind to doxycycline and the complex will bind to TRE, which activates transcription.  
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Figure 8: Functional Validation of H9-iCas9 Line (Clone 4):  
 
From Figure 8, after 48 hours of exposer to doxycycline, Cas9 expression can be 
observed after antibody staining.   
 
 
Generating an NPC-specific fluorescent reporter hPSC line 
 Beginning this project is similar to the start of the generation of iCas9 hPSC line 
except the CITED1 gene was targeted rather than the AAVS1 locus. pSpCas9(BB)-2A-
GFP was digested with Bbs1 and the digested plasmid DNA was obtained through gel 
purification. Primers/oligos were created for 4 hCITED1 gRNAs. 
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Primer 
ID Name Sequence (5’-3’) 
025 
hCITED1 gRNA 
Fwd 1 CACCGAATGAGTTTGACTTCACTG 
026 
hCITED1 gRNA 
Rev 1 aaacCAGTGAAGTCAAACTCATTC 
027 
hCITED1 gRNA 
Fwd 2 CACCGCCAAGTGTCCCTAAAGATGG 
028 
hCITED1 gRNA 
Rev 2 aaacCCATCTTTAGGGACACTTGGC 
029 
hCITED1 gRNA 
Fwd 3 CACCGTTTATTTACAACAGAATTGG 
030 
hCITED1 gRNA 
Rev 3 aaacCCAATTCTGTTGTAAATAAAC 
031 
hCITED1 gRNA 
Fwd 4 CACCGCCTCCATCTTTAGGGACACT 
032 
hCITED1 gRNA 
Rev 4 aaacAGTGTCCCTAAAGATGGAGGC 
 
Table 4: Cited1 gRNAs: Targeting hCITED1 locus at stop codon  
 
Each pair of oligo were phosphorylated and annealed. Each pair were ligated into 
the Bbs1 digest pSpCas9(BB)-2A-GFP. The 4 pairs of gRNA ligation reactions were 
transformed into DH5a competent cells and grown on LB Ampicillin plates overnight at 
37°C. The transformation was successful for 3 out of 4 plates. gRNA 4 on plate 4 did not 
grow. Colonies were picked from the 3 plates and 6 clones were grown in LB ampicillin 
medium. DNA was extracted for the bacterial cultures using QIAGEN Spin MiniPrep 
Kit. DNA for 6 clones were collected: Clones 1.1, 1.2, 2.1, 2.2, 3.1, 3.2. Cas9 nuclease 
containing a gRNA for CITED1 was completed. The clones were sequence verified and 
stored at -20°C for downstream use.  
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The donor vector pCITED1-P2A-eGFP-Puro needed to be created for the 
CRISPR/Cas9 mediated gene-editing in hESC transfection protocol. We chose the 
available OCT4-2A-eGFP-PGK-Puro plasmid to use as a template to construct our 
targeting vector pCITED1-P2A-eGFP-Puro. It contains an eGFP gene and a puromycin 
selectable drug cassette, which are flanked by homology regions for the human OCT4 
gene (which is not relevant to this project). Our strategy was to replace the OCT4 
sequences with CITED1 homology arms, which would then provide a donor vector to 
introduce eGFP into the CITED1 locus. The OCT4-2A-eGFP-PGK-Puro plasmid was 
ordered from Addgene as a bacteria agar stab. After growing up the bacteria and 
extracting the plasmid DNA, a restriction enzyme test was run to verify the plasmid 
DNA. 
 
 
Figure 9: OCT4-2A-eGFP-PGK-Puro Restriction Enzyme Digest: Lane 1: 
Undigested Plasmid. Lane 2: BamHI Digest. Lane 3: NheI Digest. Lane 4: NotI Digest. 
Lane 5: AscI Digest. 
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BamHI cuts OCT4-2A-eGFP-PGK-Puro once at cut site 295bp. NheI cuts the plasmid 
once at cut site 1045bp. NotI cuts the plasmid once at cut site 4465bp. AscI cuts the 
plasmid once at 3716bp. All 4 restriction enzymes linearize OCT4-2A-eGFP-PGK-Puro 
and should express the size of the plasmid which is 8025bp. From the gel, all 4 restriction 
enzymes produced the desired bands and the plasmid DNA can be safely confirmed as 
OCT4-2A-eGFP-PGK-Puro.  
 
 
Figure 10: OCT4-2A-eGFP-PGK-Puro Diagram 
 
 
Cloning pCITED1-P2A-eGFP-Puro 
The first step in the cloning process to is create the CITED1 homology arms. PCR 
reactions used the Bio-rad iProof High-Fidelity PCR Kit.  
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Primer 
ID Name Sequence (5'-3') 
015 
hCITED1 Right HA 
Fwd 1 ctGGCGCGCCTGCCAAGTGTCCCTAAAGATGG 
016 
hCITED1 Right HA 
Rev 1 ctGCGGCCGCttgaaagtgcttgctagggg 
017 
hCITED1 Right HA 
Rev 2 ctGCGGCCGCcagagtgtccaggacattgg 
018 
hCITED1 Right HA 
Rev 3 ctGCGGCCGCgcaagggatagatcgccaaa 
019 
hCITED1 Right HA 
Rev 4 ctGCGGCCGCactcaagaccagctcagagt 
020 
hCITED1 Left HA 
Fwd 1 ctaGGATCCgcaaaaccactctgttgaagaga 
021 
hCITED1 Left HA 
Fwd 2 ctaGGATCCagcaaaaccactctgttgaagag 
022 
hCITED1 Left HA 
Fwd 3 ctaGGATCCtaggtgcattacccagtgtcc 
023 
hCITED1 Left HA 
Fwd 4 ctaGGATCCgaagtgcaggtaggaaccttct 
024 
hCITED1 Left HA 
Rev 1 ctaGCTAGCGCAGCTAGATGGAAAGTCCG 
 
Table 5: Primers of Homology Arms for hCITED1 cloning.  
 
 
Primers 15 and 16 were used for the right homology arm. Primers 22 and 24 were 
used for the left homology arm. The PCR products were purified using the QIAGEN 
PCR Purification kit. The CITED1 homology arms needed to be prepped for downstream 
ligation reactions and this was done by restriction enzyme digest. The CITED1 Left 
Homology Arm was digested with BamHI on the 5’ end and NheI on the 3’end, and the 
CITED1 Right Homology Arm was digested with SgsI on 5’ and NotI on 3’. Both 
digestions were incubated at 37°C for 1 hour and stored at -20°C. 
The next step was to clone the CITED1 Homology Arms into OCT4-2A-eGFP-
PGK-Puro. The Left Homology Arm was cloned in first. OCT4-2A-eGFP-PGK-Puro was 
 36 
digested with BamHI and NheI to remove the OCT4 left homology arm. To confirm, a 
gel was run where a 7,275bp and 750bp should be present. The larger fragment contains 
the vector backbone, and it was purified from the agarose gel.  
 
 
 
Figure 11: Oct4-GFP digested with BamHI and NheI 
 
 
 A ligation reaction was set up between the BamHI and NheI digest OCT4-2A-
eGFP-PGK-Puro and the digested CITED1 Left Homology Arm. This ligation was 
transformed into competent DH5a cells. Colonies were grown up for DNA MiniPrep 
extraction. To confirm that we have the correct plasmid, restriction enzyme BpiI was 
used. BpiI cuts our desired plasmid once but does not cut the original plasmid. There is 
no BpiI cut site in OCT4-2A-eGFP-PGK-Puro. Restriction Enzyme AscI also cuts the 
plasmid once. A double digest will produce a 5.1kb and 3.2kb bands.  
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Figure 12: Oct4-GFP + CITED1 LHA: Lane 1: Undigested Plasmid. Lane 2: BpiI 
digest. Lane 3: BpiI and AcsI digest.  
 
 
 
From the restriction enzyme test, it we were confident that we had successfully cloned in 
the CITED1 LHA into OCT4-2A-eGFP-PGK-Puro.  
The next step is to remove the Oct4 Right Homology Arm and replace it with the 
CITED1 Right Homology Arm. The Oct4-GFP + CITED1 LHA plasmid was digested 
with AscI and NotI which removed the Oct4-GFP right homology arm. A confirmation 
gel was run to determine if the plasmid had the correct sites. The digest produced 2 bands 
of 7.5kb and 750bp which is the correct band sizes. 
Next the digested CITED1 Right Homology Arm is ligated with the OCT4-2A-
eGFP-PGK-Puro containing the LHA. These ligations were transformed into DH5a cells 
and colonies grew. To see if the clones expressed the final product: pCITED1-P2A-
eGFP-Puro a restriction digest with NheI was performed. NheI cuts pCITED1-P2A-
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eGFP-Puro twice and the original OCT4-2A-eGFP-PGK-Puro and OCT4-2A-eGFP-
PGK-Puro containing the LHA once. 
 
 
Figure 13: pCITED1-P2A-eGFP-Puro NheI Digest: Lane 1: Parent Vector 
(Oct4-GFP with LHA) Lane 2: Original OCT4-2A-eGFP-PGK-Puro. Land 3: 
Clone 1. Lane 4: Clone 1.2. Lane 4: Clone 2. Lane 5 Clone 4.  
 
 
From analyzing the gel, all clones expressed the desired genotype and we can be 
confident that the clones express pCITED1-P2A-eGFP-Puro.  
With pCITED1-P2A-eGFP-Puro and pSpCas9(BB)-2A-GFP with the hCITED1 
gRNA available, the CRISPR/Cas9 mediated gene-editing in H9 hESC transfection 
protocol was started. The antibiotic selection marker used in this transfection was 
puromycin. The plasmid created pCITED1-P2A-eGFP-Puro expressed the puromycin 
resistant gene.  
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Figure 14: CITED1 Knock-in Strategy 
 
PCR: 
48 + 49 = 1858bp (WT) 
48 + 49 = 4533bp (KI) 
48 + 50 = 1732bp (GFP)  
24 clones were collected and genotyped using allele-specific PCR. The following primers 
were designed. 
 
 
Primer Name Sequence (5’-3’) 
048 hCITED1-eGFP Screening Ext Fwd 1 AGGCTCTGAAATGCCAACAA 
049 hCITED1-eGFP Screening Ext Rev 1 actcaagaccagctcagagt 
050 hCITED1-eGFP Screening INT Rev 1 ATGTTGTGGCGGATCTTGAA 
 
Table 6: Genotyping Primers 
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Figure 15: CITED1 Allele 
 
 
Clones that have been successfully transfected will express the GFP insert in cells 
that express CITED1, such as nephron progenitor cells. Primer 50 is located within the 
GFP insert and amplification of this primer will indicate the presence of the GFP insert. 
Primers 48 and 49 on the original WT CITED1 gene produces a 1858bp band. 
Successfully transfected clones will express a larger 4533bp band with Primers 48 and 
49. This is due to the 2A, GFP, PGK, and PuroR inserts being incorporated into the gene 
and increase the size in-between Primers 48 and 49.  
 
 
 
 
 
 
Figure 16: PCR Screening with Primers 48 and 50: Of the 24 clones, 21 expressed a 
positive 1732bp indicating the present of the GFP insert.  
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Figure 17: PCR Screening with Primers 48 and 49:  
 
 
 
2 out of 23 clones, 12 and 13, expressed no GFP insert (+/+). Clones that were 
successfully transfected with our desired inserts will express a 4533bp band with Primers 
48 and 49 compared to the WT which will express a 1858bp band. 12 out of 23 clones 
expressed a GFP band and a 1858bp band, (GFP/+). Clones 4, 5, 6, 7, 9, 16, 19, 20, 21, 
22, 23, 24. 9 out of 23 clones expressed a GFP band and the 4533bp band. Clones 1, 2, 3, 
10, 11, 14, 15, 17, 18. Clone 8 was not included due to no band expression with Primers 
48 and 49.  
The next step in the CITED1 project, is to transfect with Cre recombinase to 
remove PGK and PuroR via the LoxP sites, then test clones for GFP expression when 
differentiated into kidney progenitor cells. These steps are currently still ongoing. 
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DISCUSSION 
 
 The focus of this project was to create tools to better understand human kidney 
development. Even with the great advances in learning about the human genome, 
physiology, and anatomy, the understanding of embryonic development is still minimal40. 
Recent research with human pluripotent stem cells has provided new insight on human 
embryonic development. Human pluripotent stem cells have the ability to self-renew 
indefinitely in culture while keeping the ability to differentiate into any cell type in the 
human body 41. In vitro, the hPSCs culture system provides a rapid and cost-effective 
way to study a specific gene during developmental processes and offers unlimited self-
renewal capacity which is ideal for high-throughput screening40. Given the usefulness of 
hPSCs on elucidating the mechanisms of human kidney development, the genetic tools 
developed in this study look to provide new insights on human kidney development. 
 One of the aims of the study, designing an inducible hPSC line, was successfully 
created and the functionally of the cell line was validated. Using CRISPR/Cas9-mediated 
homology directed repair, inducible doxycycline hPSC lines were created (iCas9 line). 
When exposed to doxycycline, the cell line revealed widespread Cas9 expression, 
validating the functionality of the cell line. In future studies, we look to use this 
multifunctional line to mediate further genetic modification, inducible gene knockout and 
lineage tracing strategies.  
The second aim of the study, generating a nephron progenitor cell-specific 
fluorescent reporter hPSC line, is still ongoing but results have been promising. So far 
cell lines with GFP knocked in to the human CITED1 locus have been produced. These 
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lines have been genotyped using allele-specific PCR reactions. The next step in this 
project is to transfect the cell lines with Cre to remove PGK and PuroR in the allele. 
When this line is completed it will be used for live imaging of NPC behavior and easy 
identification and isolation of NPCs for downstream analysis. The line will also aid in 
selection and maintenance of multipotent NPCs. We also plan to use these fluorescently 
labeled NPCs in future kidney organoid differentiation experiments due to the importance 
NPCs have during renal development.  
With many areas of human kidney development poorly understood, our study 
aims to generate tools to help provide better insight into the field. We hope that the tools 
created in this study will provide us and other researchers with ways to interrogate human 
kidney development. 
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